Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.
The pharmacokinetics and pharmacodynamics of sedatives and analgesics are significantly altered in the critically ill. These changes may account for the large differences in drug dosage requirements compared with other patient populations. Drugs that in other settings may be considered short-acting often have significantly altered onset and duration of action in critically ill patients, necessitating a change in dosage. Of the benzodiazepines, lorazepam is the drug whose parameters are the least likely to be altered in critical illness. The presence of active metabolites with other benzodiazepines complicates their use during periods of prolonged use. Similarly, the presence of active metabolites of morphine and pethidine (meperidine) warrants caution in patients with renal insufficiency. The fewer cardiovascular effects seen with high-potency opioids, such as fentanyl and sufentanil, increase their usefulness in haemodynamically compromised patients. The pharmacodynamics of propofol are not significantly altered in the critically ill. Ketamine should be used with a benzodiazepine to prevent the emergence of psychomimetic reactions. Lower sedative doses of benzodiazepines and anaesthetics may not provide reliable amnesia. Barbiturates and propofol probably do not induce hyperalgesia and lack intrinsic analgesic activity. The antipsychotic agent haloperidol has a calming effect on patients and administration to the point of sedation is generally not necessary. Combinations of sedatives and analgesics are synergistic in producing sedation. The costs of sedation and analgesia are very variable and closely linked to the pharmacokinetics and pharmacodynamics of the drug. Monitoring of sedation and analgesia is difficult in uncooperative patients in the intensive care unit. In the future, specific monitoring tools may assist clinicians in the regulation of infusions of sedative and analgesic agents.
Wagner
B K
BK
Department of Pharmacy Practice, Rutgers University, College of Pharmacy, Piscataway, New Jersey, USA. bwagner@rci.rutgers.edu
O'Hara
D A
DA
D000700:Analgesics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000493:pharmacokinetics; D003422:Critical Care / Q000379:methods*; D016638:Critical Illness; D017850:Economics, Pharmaceutical; D006801:Humans; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008991:Monitoring, Physiologic; D011595:Psychomotor Agitation / Q000378:metabolism*
D000700:Analgesics; D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives